Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110. doi:10.1016/j.ccr.2009.12.020
Tam WF, Gu TL, Chen J, et al. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood. 2008;112(5):1981-92. doi:10.1182/blood-2007-07-103010
Antipova AA, Stockwell BR, Golub TR. Gene expression-based screening for inhibitors of PDGFR signaling. Genome Biol. 2008;9(3):R47. doi:10.1186/gb-2008-9-3-r47
Sherwood RI, Jitianu C, Cleaver O, et al. Prospective isolation and global gene expression analysis of definitive and visceral endoderm. Dev Biol. 2007;304(2):541-55. doi:10.1016/j.ydbio.2007.01.011
Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10(4):321-30. doi:10.1016/j.ccr.2006.09.005
Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10(4):331-42. doi:10.1016/j.ccr.2006.09.006
Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-35. doi:10.1126/science.1132939
Taylor TD, Noguchi H, Totoki Y, et al. Human chromosome 11 DNA sequence and analysis including novel gene identification. Nature. 2006;440(7083):497-500. doi:10.1038/nature04632
Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet. 2005;37(1):48-55. doi:10.1038/ng1490
Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 2004;6(6):565-76. doi:10.1016/j.ccr.2004.10.014